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Abstract
Background Metabolic syndrome (MetS) is a complex
metabolic disease connected especially with lipid and
carbohydrate disturbances. It is postulated that oxidative
stress (OS) is linked to metabolic syndrome, constituting a
novel component of its pathogenesis.
Aim We aimed to examine the plasma level of oxida-
tively modified proteins––advanced oxidation protein pro-
ducts (AOPP) and ischemia modified albumin (IMA)––as
well as thiol (SH) groups and evaluate their connection
with metabolic agents in relation to MetS prevalence.
Subjects and methods The levels of AOPP, IMA and SH
groups were measured spectrophotometrically in 106
patients with MetS risk factors and in 32 control subjects.
Results The levels of examined parameters differed sig-
nificantly between patients with MetS risk factors and the
control group. AOPP significantly correlated with glucose
(r = 0.30, p = 0.008), HDL-Ch (r = -0.34, p = 0.005),
TG (r = 0.48, p \ 0.001) and fibrinogen (r = 0.37,
p \ 0.001). The levels of AOPP and IMA increased
progressively with the number of MetS risk factors, being
the most significant for AOPP. The highest values of AOPP
were associated with the presence of at least three risk
factors. Only AOPP were an independent determinant for
MetS occurrence in the studied population (OR = 2.72,
p = 0.04). Mutual dependence between metabolic, oxida-
tive stress and inflammatory parameters was revealed.
Conclusions Oxidative modifications of proteins are
increased in MetS and accumulation of MetS risk factors
enhances manifestation of OS. AOPP is the most appro-
priate parameter for determination of OS, with potential
diagnostic value in MetS patients.
Keywords Metabolic syndrome  Advanced oxidation
protein products  Ischemia modified albumin  Oxidative
stress  Serum albumin modifications
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Introduction
Metabolic syndrome (MetS), currently one of the major
public health issues, is defined as a cluster of different risk
factors that occur together and significantly increase the
risk of coronary artery disease, stroke, atherosclerosis and
type 2 diabetes. The mechanism of metabolic disturbances
associated with MetS is complex, and not yet fully
understood, but involves obesity, abnormal lipid and glu-
cose levels and elevated blood pressure. Moreover, sub-
clinical inflammation and hemostatic disturbances are also
reported to be favorable conditions for MetS development
[1–3]. All these abnormalities are connected in different
aspects with oxidative/antioxidative imbalance. Recently,
it has been claimed that oxidative stress (OS) is closely
linked to MetS. Moreover, it is known that OS plays a
crucial role in the injury response to hypoxia–ischemia
conditions, which is manifested by excessive reactive
oxygen species (ROS) generation and subsequent intensi-
fication of OS [4, 5]. Oxidative stress and exacerbation of
disturbances connected with MetS constitute a novel
important component of the pathogenesis of metabolic
syndrome [6, 7].
ROS are able to react with most macromolecules, but
proteins are affected to the highest degree. Albumin,
because of its abundance in the blood, accounts for almost
all of the excess plasma protein oxidation. The oxidative
modification of proteins plays an important role in patho-
genesis and development of various metabolic disturbances
[8, 9]. A growing body of evidence supports the concept
that protein modifications are connected with the increase
of MetS prevalence. While the role of protein oxidation is
well established in obesity, diabetes mellitus, arterial
hypertension and dyslipidemia, only a few data concern
protein oxidation in MetS [10, 11]. Therefore, we decided
to estimate the plasma levels of two modified forms of
albumin––advanced oxidation protein products (AOPP)
and ischemia modified albumin (IMA)––which are con-
sidered as representative markers of oxidative stress
intensity and degree of oxidative damage of proteins in
numerous diseases [12, 13].
Advanced oxidation protein products (AOPP) are an
oxidatively modified form of proteins (mainly albumin)
created as the result of excessive generation of ROS and
reactive chlorine species (mainly chloramine produced by
myeloperoxidase in activated neutrophils). These highly
reactive agents cause structural and functional changes of
the albumin molecule, leading to the reduction of its
antioxidant properties, and predisposing to its aggregation
and deposition in tissues. AOPP are abundant in dityrosine
residues, disulfide bridges, carbonyl groups and cross-links
[14]. Moreover, AOPP may also cause subsequent activa-
tion of a cascade of ROS production and thereby enhance
its adverse oxidizing action. The increased formation of
AOPP is well documented in different diseases (e.g. dia-
betes, obesity, atherosclerosis) [9, 15, 16].
Ischemia modified albumin (IMA) is a modified form of
albumin, created as a result of ROS action under reduced
oxygen tension conditions in response to hypoxia or aci-
dosis. During ischemia, the increased ROS generation
inducing structural modification of albumin results in a
reduction of its ability to bind endogenous and exogenous
ions. Modification of its N-terminal amino acids (Asp-Ala-
His) leads to decreased transition metal (Co2?, Ni2?, Cu2?)
binding capacity of the albumin molecule, which is the
basis of its measurement in biological fluids [17]. The most
common condition connected with such disturbances is
tissue ischemia caused mainly by myocardial infarction
and ischemic heart disease. Moreover, increased levels of
IMA are observed in diabetes (especially when compli-
cated with hypertension), atherosclerosis and intense
physical exertion [18–20].
Another effect of ROS action is oxidation of sulfhydryl
groups (SH) in albumin and their depletion in blood, which
subsequently exacerbates functional and structural distur-
bances of attacked macromolecules [21].
To our knowledge, in the currently available literature,
there is no information on the plasma levels of above-
mentioned oxidatively modified forms of albumin, that is
AOPP and IMA, in terms of their connection with risk
factors of metabolic syndrome [5, 22]. It is still unclear
whether the accumulation of factors related to MetS
increases the OS. Following these assumptions, in this
study, we estimated plasma levels of advanced oxidation
protein products and ischemia modified albumin as well as
SH groups in patients with different numbers of MetS risk
factors and in a control group. We also examined the
connection of these modified forms of albumin with dif-
ferent metabolic agents with regard to occurrence of MetS.
Materials and methods
Patients
In this study, 106 patients (58 female and 48 male) of the
Department and Clinic of Internal and Occupational Dis-
eases and Hypertension of Wroclaw Medical University,
with different numbers of risk factors of metabolic syn-
drome, were involved. Exclusion criteria for the study
included: current smokers, acute inflammation state,
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current cardiovascular events, malignant and liver diseases.
Thirty-two healthy controls (17 female and 15 male) were
recruited from the staff of Wroclaw Medical University on
the occasion of periodic health examinations. Routine
medical check-ups showed no evidence of inflammation or
abnormalities in lipid and carbohydrate metabolism,
hypertension or kidney disorders. The anthropometric and
biochemical characteristics of all participants are given in
Table 1. The study was approved by Wroclaw Medical
University Bioethics Committee. All participants were
informed about the aim of these investigations and they
gave consent to participate in this study.
According to the International Diabetes Federation
recommendation [23], the diagnostic criteria for metabolic
syndrome were applied. MetS was diagnosed when at least
three of the following five factors were present: abdominal
obesity described by waist circumference (WC C80 cm for
women and C94 cm for men), high-density lipoprotein
cholesterol (HDL-Ch) concentration below 50 mg/dL
(1.3 mmol/L) for women and 40 mg/dL (1.0 mmol/L) for
men, triglyceride (TG) concentration C150 mg/dL
(1.7 mmol/L) or current treatment for triglyceride abnor-
malities, blood pressure (BP) C130/85 mmHg (or current
use of antihypertensive medications) and fasting glu-
cose C100 mg/dL (5.6 mmol/L) or previously diagnosed
type 2 diabetes. Among the studied population, 47 % of
patients received hypotensive agents, 24 % hypoglycemic
and 29 % antidyslipidemic ones. Diabetes type 2 was
previously recognized in 31 patients and atherosclerosis in
34.
On the basis of MetS diagnostic criteria, patients were
divided into three groups according to the number of risk
factors of metabolic syndrome: group A––with 1 or 2 risk
factors of metabolic syndrome; group B––with 3 MetS risk
factors; and group C––with 4 or 5 risk factors of MetS.
Plasma levels of modified forms of albumin, that is AOPP
and IMA, as well as SH groups, were analyzed in these
groups. Furthermore, patients were divided into subgroups
according to quartiles of increasing concentration of AOPP
and also according to the presence of diabetes or athero-
sclerosis (details in ‘‘Results’’ section).
Laboratory measurements
The laboratory parameters (given in Table 1) were
immediately measured in blood samples collected by
venous puncture technique after an overnight fast (8–12 h)
in appropriate tubes (Sarstedt AG&Co, Germany) with or
without an anticoagulant agent, and specimens were rou-
tinely centrifuged at 2,5009g for 10 min to obtain plasma
or serum. In the whole blood, the number of white blood
cells (WBC), platelets and erythrocyte sedimentation rate
(ESR) were estimated. The serum was used to assess total
cholesterol (Total-Ch), HDL-Ch and low-density lipopro-
tein cholesterol (LDL-Ch), triglycerides, creatinine and
C-Reactive Protein (CRP). The glucose and fibrinogen
concentrations were measured in plasma samples (col-
lected into tubes with EDTA and sodium fluoride and
citrate, respectively). These routine biochemical parame-
ters were measured by standard methods using Cobas Mira
Plus (Roche Diagnostics, Basel, Switzerland) and Konelab
20i (Thermo Scientific, Waltham, USA) automated
analyzers.
Levels of modified forms of proteins (AOPP and IMA)
as well as SH groups and albumin concentrations were
measured in plasma samples (collected into tubes con-
taining 16 IU/mL heparin). These plasma samples were
immediately frozen and stored at -85 C (not longer than
3 months) until the simultaneous determinations of these
parameters. All determinations were done in duplicate.
AOPP were measured spectrophotometrically according to
Table 1 Anthropometric and biochemical characteristics of all










Age (years) 55.48 ± 15.92 53.08 ± 13.09 p = 0.3466
BMI (kg/m2) 29.41 ± 5.44 25.31 ± 2.81 p = 0.0096
WC (cm) 89.72 ± 10.93 78.34 ± 7.44 p < 0.001
SBP (mmHg) 148.74 ± 31.81 122.05 ± 11.39 p < 0.001
DBP (mmHg) 88.49 ± 17.63 75.05 ± 7.68 p < 0.001
ESR (mm) 15.51 ± 11.36 9.62 ± 5.98 p = 0.0656
CRP (mg/L) 3.57 ± 2.08 2.25 ± 1.72 p < 0.001
Fibrinogen (g/L) 3.97 ± 1.91 3.45 ± 0.11 p = 0.2605
WBC (109/L) 7.14 ± 2.10 6.65 ± 1.63 p = 0.2910
Platelet (109/L) 229.24 ± 71.94 238.58 ± 76.54 p = 0.8574
Glucose
(mmol/L)
5.93 ± 1.70 5.16 ± 0.38 p = 0.0201
Total-Ch
(mmol/L)
5.34 ± 1.54 4.76 ± 0.67 p = 0.0812
HDL-Ch
(mmol/L)
1.27 ± 0.36 1.55 ± 0.34 p < 0.001
LDL-Ch
(mmol/L)
3.09 ± 1.18 2.79 ± 0.64 p = 0.1357
TG (mmol/L) 1.56 ± 0.77 1.19 ± 0.29 p = 0.0332
Creatinine
(lmol/L)
94.68 ± 39.45 93.36 ± 12.67 p = 0.1074
BMI body mass index, CRP C-reactive protein, DBP diastolic blood
pressure, ESR erythrocyte sedimentation rate, HDL-Ch HDL choles-
terol, LDL-Ch LDL cholesterol, SBP systolic blood pressure, TG
triglyceride, Total-Ch total cholesterol, WBC white blood cells, WC
waist circumference
A two-tailed p value of less than 0.05 was considered significant
(bolded)
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the method by Witko-Sarsat et al. [24] described previously
[15]. IMA was also measured spectrophotometrically
according to Bar-Or et al. [25] as described previously
[19]. The concentration of SH groups was determined
using 5-50-dithio-bis(2-nitrobenzoic acid) solution (DTNB)
according to the method of Rice-Evans et al. [26], as
described previously [15]. The bromocresol purple (BCP)
dye-binding method was used for the estimation of serum
albumin [27].
Statistical analysis
Data are expressed as mean ± standard deviation
(X ± SD). The statistical analysis was performed using
Statistica PL for Windows (v.10.0). The normality of
distribution of all variables was evaluated by Shapiro–
Wilk test. Comparisons between examined groups were
performed by Mann–Whitney U test or Student’s t test.
Differences between groups of patients with different
numbers of risk factors of MetS were evaluated by ana-
lysis of variance (ANOVA) followed by multiple com-
parison post hoc Fisher test. Spearman rank correlations
were used to test the relationships of AOPP, IMA and SH
with routine laboratory parameters. To identify indepen-
dent factors for the presence of MetS, multivariate ana-
lysis was performed and the effect size was reflected as
the odds ratio (OR) with 95 % confidence interval (CI).
Correspondence analysis was performed to evaluate the
association between number of MetS risk factors and
quartiles of AOPP. Canonical analysis was used to eval-
uate the influence of modified forms of albumin (AOPP
and IMA) together with inflammatory parameters on MetS
risk factors. A value of p less than 0.05 was considered as
statistically significant.
Results
The parameters of anthropometric and biochemical char-
acteristics of the study participants (given in Table 1), as
expected, varied between patients with MetS risk factors
and the control group. The BMI and waist circumference,
systolic and diastolic blood pressure, CRP, fasting glucose
as well as triglycerides were significantly higher and HDL
cholesterol was lower in these patients. However, age,
WBC and platelet count, ESR, fibrinogen, creatinine as
well as total cholesterol and LDL-Ch did not show sig-
nificant differences. From Spearman correlation analysis, it
was revealed that AOPP were associated with glucose
(r = 0.30, p = 0.0076), HDL-Ch (r = -0.34,
p = 0.0046), TG (r = 0.48, p \ 0.001), and fibrinogen
(r = 0.37, p = 0.0004). IMA was not associated with any
routine biochemical parameter and SH groups correlated
only with fibrinogen (r = -0.34, p = 0.0054).
Data concerning modified forms of albumin (AOPP and
IMA) as well as SH groups in control subjects (without
MetS risk factors) and in patients with MetS risk factors,
also subdivided into three groups, according to the number
of MetS risk factors (A––with 1 or 2 risk factors, B––with
3 risk factors, C––with 4 or 5 risk factors of MetS) are
presented in Table 2. Significant differences between
control subjects and each group of patients are observed in
all analyzed parameters. Almost 60 % increase in AOPP
concentration, 70 % in IMA level and about 20 % decrease
in SH concentration (p \ 0.001, 0.001 and 0.05, respec-
tively) were observed in MetS patients, while concentration
of plasma albumin did not differ. Analyzing differences
between groups of patients with different numbers of MetS
risk factors (A, B and C), we also found no differences in
albumin concentration. However, concentration of AOPP
Table 2 The levels of albumin and its modified forms (AOPP and IMA) and SH groups in plasma of control subjects and patients (all and in





Group A (1–2 risk
factors) (n = 39)
Group B (3 risk
factors) (n = 31)
Group C (4–5 risk




Albumin (g/L) 43.18 ± 7.09 41.32 ± 6.29 43.24 ± 5.64 41.68 ± 6.54 40.04 ± 8.62 p = 0.876
AOPP (lmol/L) 90.44 ± 30.39 142.44 ± 69.00 117.44 ± 42.21 129.69 ± 41.71 180.52 ± 80.02 p \ 0.001
p \ 0.001C p = 0.049C p = 0.013C p \ 0.001C
p = 0.002A
p = 0.014B
IMA (ABSU) 0.315 ± 0.093 0.530 ± 0.153 0.494 ± 0.133 0.553 ± 0.152 0.552 ± 0.144 p \ 0.001
p \ 0.001C p \ 0.001C p \ 0.001C p \ 0.001C
SH groups (lmol/L) 664.90 ± 112.56 552.39 ± 140.58 556.48 ± 123.48 552.98 ± 139.39 547.48 ± 149.97 p = 0.025
p = 0.015C p = 0.014C p = 0.015C p = 0.023C
Significant differences versus: C control group, A patients from group A, B patients from group B (assessed by Mann–Whitney U test or Fischer
post hoc test)
A two-tailed p value of less than 0.05 was considered significant
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increased progressively with the increasing number of risk
factors and significant differences were observed between
group C and each of the remaining groups. The level of
IMA was somewhat higher in groups B and C than in group
A, but the increase was not significant. Concentration of
SH groups had a trend to decrease slightly but without
statistical significance.
On the basis of the above observations, we carefully
examined the association of AOPP concentration with
number of MetS risk factors. Quartiles of AOPP concen-
tration (Q1–Q4) were calculated and patients were divided
into four subgroups according to increasing values of
AOPP: quartile 1 (Q1) included values of AOPP B99.29
lmol/L, quartile 2 (Q2) [99.29 and B124.65 lmol/L,
quartile 3 (Q3) [124.65 and B158.28 lmol/L, and quartile
4 (Q4) [158.28 lmol/L. The variable describing the
number of MetS risk factors was categorized into five
subgroups (from 1 to 5 risk factors). In correspondence
analysis, we constructed a 2-dimensional model
(v2 = 28.421, df = 12, p = 0.005), which explained
92.45 % of the total inertia (the first dimension explained
64.40 % and the second 28.05 % of total inertia). An
illustration of this analysis is presented in Fig. 1. Inter-
preting this plot, groups ‘‘4’’ and ‘‘1’’ (for number of MetS
risk factors) and ‘‘Q4’’ and ‘‘O1’’ (for quartiles of AOPP)
had the greatest participation of total inertia in the first
dimension. Groups ‘‘5’’ and ‘‘1’’ (for number of MetS risk
factors) and ‘‘Q3’’ and ‘‘O1’’ (for quartiles of AOPP) had
the greatest participation of total inertia in the second
dimension. Statistical analysis of the final configuration of
points demonstrated that 71 % of patients with only one
MetS risk factor belong to Q1 of AOPP concentration and
58 % of patients with four MetS risk factors belong to Q4.
In turn, 52 % of patients from Q4 had four MetS risk
factors, and 26 % had three of them. Furthermore, among
patients from Q1, only 5 % had more than three MetS risk
factors and among patients with one MetS risk factor there
is nobody from Q3 and Q4.
Multivariate analysis for independent determinants of
metabolic syndrome presence is presented in Fig. 2. We
compiled conventional MetS risk factors with parameters
of albumin modification examined by us. The following
variables were categorized: sex, age, WC, HDL-Ch, TG,
glucose, BP, as well as AOPP, IMA and SH groups. As
revealed, the constructed model was statistically significant
(OR = 2.25, p = 0.0134) and variables with the greatest
impact on statistical significance of this model were:
hypertriglyceridemia (OR = 21, p \ 0.001), abdominal
obesity (assessed by waist circumference, OR = 8.5,
p \ 0.001), hyperglycemia (OR = 4.95, p = 0.0012),
HDL hypocholesterolemia (OR = 3.5, p = 0.0155) as well
as increased AOPP concentration (OR = 2.72,
p = 0.0493). Obviously, among examined modified forms
of albumin, only AOPP were an independent risk factor for
metabolic syndrome occurrence in the studied population.
We also investigated whether the presence of diabetes or
atherosclerosis had any influence on values of this
parameter. We divided patients into subgroups according to
Fig. 1 Association between
quartiles of AOPP concentration
and number of MetS risk factors
in 2-dimensional model
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two criteria: presence or absence of diabetes, and presence
or absence of atherosclerosis. One-way analysis of variance
showed that there were no significant differences between
patients without MetS and with or without diabetes (108.62
vs 130.11 lmol/L) as well as between patients with MetS
and with or without diabetes (155.65 vs 151.38 lmol/L).
We found an increase in IMA levels in patients with MetS
with concomitant atherosclerosis in comparison to patients
with MetS without atherosclerosis (0.578 vs 0.533 absor-
bance units [ABSU]). However, in patients without MetS,
the presence of atherosclerosis also had an impact on IMA
level (0.537 vs 0.501 ABSU).
In addition, we correlated selected MetS risk factors,
reflecting carbohydrate and lipid disorders (set of criterion
variables) with selected parameters reflecting inflammation
and oxidative stress (set of predictor variables) using
canonical analysis. We obtained a statistically significant
(p = 0.048) model (canonical r = 0.776), in which three
canonical variables (CRP, AOPP and IMA) exhibited
100 % variability in this set and 100 % variability in the set
of MetS risk factors (glucose, HDL-Ch and TG). AOPP
had the largest canonical weight of predictor variables
(0.75). Moreover, redundancy of the set of criterion vari-
ables was 34 and 43 % in the set of predictor variables.
Discussion
It is known that MetS patients exhibit activation of bio-
chemical pathways leading to increased production of
reactive oxygen species and numerous studies describe
oxidative status in individual components of MetS. In fact,
OS, due to the production of ROS, impairment of antiox-
idant enzymatic defenses, oxidative modifications of many
macromolecules (mainly proteins and low-density lipo-
proteins), and their deposition in tissues, organs and vas-
cular wall, may be additional component of the
pathogenesis of MetS [28–30]. There is a current theory
that OS could be an early event in the pathology of the
chronic diseases associated with the metabolic syndrome,
not only a consequence of these disorders [7]. However,
the exact mechanism of its involvement in the development
of MetS remains unclear. This is partly due to the wide
diversity of markers which reflect OS intensity and lack of
standardization of its determination in certain cases.
In this study, we focused on selected biochemical
parameters, reflecting OS-induced modifications of the
albumin molecule. We chose AOPP as a marker of irre-
versible damage of proteins caused by OS, IMA as a
marker of hypoxia-induced OS, and SH groups as a marker
of redox status of albumin reflecting non-enzymatic anti-
oxidant defense. We revealed significantly higher levels of
AOPP and IMA with lower SH concentrations in patients
with different numbers of metabolic syndrome features in
comparison to the control group. We ascertained that
plasma level of albumin had no impact on examined
parameters (it was at a similar level in both examined
groups of participants and there were no subjects with
abnormalities in this area). Obtained results confirm that
OS is increased in patients with MetS risk factors and
Fig. 2 Multivariate analysis
for independent determinants of
metabolic syndrome
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causes direct oxidative damage to proteins in these
patients. Our findings are consistent with other investiga-
tions regarding protein oxidation in patients with full-
blown metabolic syndrome [11]. Caimi et al. [31] observed
higher concentration of carbonyl groups in these patients
and Korkmaz et al. [22] found increased AOPP levels and
pro-oxidant/antioxidant balance (PAB) values. Higher IMA
levels in MetS patients were observed by Valle-Gottlieb
et al. [5] in association with cardiometabolic risk factors in
MetS. However, to our knowledge, there is no information
about plasma levels of AOPP in combination with IMA
and SH groups in terms of their connection with risk fac-
tors of occurrence of MetS. Only a single investigation by
Demir et al. [32] has determined simultaneously AOPP and
IMA levels, but in patients with cardiac syndrome X. The
authors found an increase in OS (expressed as increased
values of PAB, AOPP and IMA) and a positive correlation
between AOPP and IMA in these patients. In contrast, we
did not detect a significant relationship between these
parameters, which may be caused by different mechanisms
of formation of these products. AOPP arise as a result of
direct action of ROS (oxidation of amino acid residues) and
subsequent structural rearrangement (creation of disulfide
bridges and other cross-linking reactions). In turn, IMA is
produced under hypoxic conditions. It is suggested that a
pro-atherogenic environment, which develops in patients
with MetS risk factors, leads to a decrease in tissue oxygen
perfusion and triggers albumin modifications.
Our study showed that among modified forms of albu-
min, AOPP exhibited the most connections with other
metabolic parameters (significant correlations with glu-
cose, HDL-Ch, TG and fibrinogen). Korkmaz et al. [22]
also found that the levels of AOPP were significantly
higher (by nearly 60 %) in MetS patients than in controls
and were positively correlated with glucose, HbA1c, TG
and insulin levels and HOMA-IR values. In this light, the
AOPP concentration is the best parameter accurately
reflecting OS in patients with MetS risk factors.
As mentioned above, the role of OS in MetS is under
intensive investigation; nevertheless, there are also still
insufficient data to determine whether the accumulation of
factors related to MetS increases the degree of underlying
OS. It is only recently that Yubero-Serrano et al. [33] in a
comparative cross-sectional study from the LIPGENE
cohort examined the relationship between the number of
MetS components and the degree of OS in MetS patients
divided into four groups (based on the number of MetS
components). The authors found significant differences in
soluble vascular cell adhesion molecule 1, H2O2, lipid
peroxidation products, ischemic reactive hyperemia, total
nitrite levels and superoxide dismutase and glutathione
peroxidase activities in plasma of examined patients. In the
present study, we analyzed the AOPP, IMA and SH group
levels in groups of patients (A–C) divided on the basis of
number of recognized MetS components, and we found
that concentrations of these parameters were significantly
different in all groups of patients versus control subjects.
Accordingly, our study showed a general tendency to ele-
vation of protein oxidation (evidence for intensification of
OS) in patients with more MetS components. It should be
highlighted that statistically significant differences were
observed even in patients with only one or two MetS risk
factors (without recognized MetS) in comparison to the
control group, which indicates that oxidative modifications
of albumin are one of the first biochemical disturbances
arising in response to metabolic abnormalities foretelling
development of MetS. This supports the hypothesis that OS
is engaged in the pathomechanism of this disease [6, 22].
Youn et al. [34] observed that mice with increased vascular
ROS production (overexpression of p22phox) developed
exaggerated obesity and increased fat mass, which was
associated with development of glucose intolerance,
reduced HDL-Ch, increased level of leptin and monocyte
chemotactic protein 1. While the high prevalence of MetS
underscores the need for early identification of risk and
introduction of prevention efforts, determination of OS
markers seems to be clinically relevant. Analyzing results
obtained in particular groups, among modified forms of
albumin, the largest percentage of changes was observed
for IMA when comparing the control group to patients
(regardless of the number of MetS risk factors). However,
only AOPP concentration differed significantly between
patients from group C and patients from groups A and B.
We suggest that AOPP adequately reflects the cumulative
effect of MetS risk factors on escalation of oxidative
damage of proteins. These results were confirmed by cor-
respondence analysis which revealed that in quartiles of
AOPP (Q1–Q4), lower AOPP concentration was closely
connected with the presence of fewer MetS risk factors and
inversely, the greater the number of risk factors the higher
the AOPP concentration. Moreover, patients belonging to
Q4 of AOPP concentration usually had more than three risk
factors.
Performed multivariate analysis also ascertained that
AOPP levels are the most relevant OS biomarker in
patients suffering from MetS and the most important
independent (after adjustment for sex and age) determinant
among examined modified forms of albumin. This indi-
cates that its determination may be equally important as
other conventional MetS risk factors. Sebekova et al. [10]
also suggest that AOPP concentration may have predictive
value to determine the degree of OS in patients with MetS
risk factors. Hopps et al. [6] even suggested that AOPP
measurement could be a diagnostic tool to identify patients
with increased risk of MetS development However,
Korkmaz et al. [22] examined the diagnostic accuracy of
J Endocrinol Invest (2014) 37:819–827 825
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AOPP by receiver operating characteristic curve analysis
and found it to be fairly low (61.8 % sensitivity and 60 %
specificity). Nonetheless, all these findings confirm that
high AOPP levels are indicative of an increase in oxidative
stress and may reflect direct oxidative damage to proteins
in MetS patients [35]. It has been proposed that the detri-
mental action of AOPP results not only from direct damage
of the protein molecule leading to its functional impair-
ment, but also from binding and activation of RAGE
receptors on the surface of various cells (especially mac-
rophages/monocytes, endothelial and vascular cells) with
subsequent activation of many signaling pathways
(including activation of mitogen-activated protein kinases
and nuclear factor kappa B) [12, 36].
We are aware of the difficulty of interpreting these data
because of heterogeneity in the studied group, especially in
the context of different co-morbidities accompanying
MetS. On the basis of our investigations, we know that
AOPP levels are significantly higher in patients with dia-
betes type 2, which is also affirmed by other authors [15,
37]. Thus, an additional question that we explored in this
study is whether the presence of diabetes had an impact on
values of AOPP. As it was revealed, in this study, the
observed increase of OS, reflected by AOPP concentration,
was not influenced by diabetes. We also presumed that
IMA levels may be influenced by the presence of athero-
sclerosis, as suggested by Kazanis et al. [38]. Atheroscle-
rotic plaque may significantly impair blood flow in vessels,
creating hypoxic conditions and favoring IMA formation.
Indeed, we found higher levels of IMA in atherosclerotic
patients with or without MetS. This means that IMA should
be interpreted with caution and may not be a reliable
marker in patients with atherosclerosis. However, it
remains a differentiating factor in patients without ath-
erosclerosis. In another study [5], it was found (by multi-
variate analysis) that IMA and MetS were associated
independently of sex, age, diabetes mellitus 2, and hyper-
cholesterolemia, so the conclusions are not unambiguous.
In this context, IMA may represent a possible indication of
progressive peripheral oxygenation insufficiency caused by
vascular dysfunction in MetS patients.
Because in our study patients with MetS risk factors are
characterized by higher inflammatory parameters (among
which only CRP differed significantly), we linked lipid-
carbohydrate MetS features with OS and inflammation in
canonical analysis. We revealed that the set of variables
AOPP, IMA, CRP explains 43 % of variance in the other
set (glucose, HDL-Ch, TG). The observed interaction
between the panel of oxidative-inflammatory parameters
and metabolic ones indicates the inseparable connection
between these factors and emphasizes the complexity of
mutual dependences in the pathomechanism of MetS. A
large body of evidence supports the concept that a state of
chronic low-level inflammation may have an important role
in MetS-related manifestations [39, 40]. It may be some-
how connected with obesity, which is the primary MetS
component. It is known that white adipose tissue secretes
various inflammatory cytokines (such as TNF alpha or IL-
6), which can subsequently alter insulin sensitivity by
triggering different key steps in the insulin signaling
pathway [41]. In aggregate, our study contributed to a
better understanding of the relationships between meta-
bolic syndrome, oxidative stress and inflammation.
We realize that this study has some limitations. The
number of estimated patients was not too large and there-
fore we could not create representative subgroups with
particular numbers of MetS risk factors. We also did not
consider the impact of medications taken and dietary
habits. Nevertheless, our study brings further evidence that
MetS is directly linked to OS, which is reflected in
increased levels of oxidatively modified forms of albumin
(AOPP and IMA) and depletion of SH concentration.
Moreover, it emerged clearly from our investigations that
accumulation of risk factors of MetS has a significant
impact on manifestation of OS. We consider AOPP con-
centration to be the most adequate parameter for determi-
nation of OS in patients with MetS risk factors, being
correlated with important metabolic parameters and asso-
ciated with the number of risk factors. Taken together,
these results suggest that AOPP may play a causal role in
the pathogenesis and development of MetS, and may be a
promising candidate for risk assessment and a potential
intervention target for MetS patients.
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